Kalzium-Sensing-Rezeptor-Antagonisten

Zusammenfassung

Kalzium-Sensing-Rezeptor-Antagonisten stellen eine in präklinischer Erprobung befindliche Option zur anabolen therapeutischen Intervention in Fällen von schwerer Osteoporose mit hoher Frakturgefährdung dar. Bisher wurden im Tierversuch vielversprechende Ergebnisse erzielt, die jedoch in klinischen Studien an Menschen aufgrund der komplexen pharmakokinetischen Anforderungen an die Substanz nicht bestätigt werden konnten. In naher Zukunft werden die Ergebnisse zweier klinischer Studien an postmenopausalen, osteoporotischen Patientinnen für das Jahr 2012 erwartet.

Summary

Calcium-sensing-receptor-antagonists belong to the class of osteo-anabolic drugs offering another therapeutic option for the pharmacologic treatment of osteoporosis with increased risk of fracture. Preclinical studies revealed encouraging results, while some human trials have failed to confirm the expectations most likely due to the challenging pharmacokinetic profile required for these drugs when given orally. In 2012 the results of two clinical studies in postmenopausal women are expected to provide more data on the potential clinical value of this new class of osteo-anabolic drugs.

Schlüsselwörter

Kalzium-Sensing-Rezeptor-Antagonisten - CaSR-Antagonisten - innovative osteoanabole Therapieformen - Parathormon

Keywords

Calcium-sensing-receptor-antagonist - calcilytics - osteo-anabolic treatment - parathormone

• Literatur

• 1 Shinagawa Y, Inoue T, Katsushima T. et al. Discovery of a Potent and Short-Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone. Acs Medicinal Chemistry Letters 2011; 02 (03) 238-242.
• 2 Roux S. New treatment targets in osteoporosis. Joint Bone Spine 2010; 77 (03) 222-228.
• 3 Yoshida M, Mori A, Kotani E. et al. Discovery of Novel and Potent Orally Active Calcium-Sensing Receptor Antagonists that Stimulate Pulselike Parathyroid Hormone Secretion: Synthesis and Structure-Activity Relationships of Tetrahydropyrazolopyrimidine Derivatives. Journal of Medicinal Chemistry 2011; 54 (05) 1430-1440.
• 4 Rachner TR, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377 (9773); 1276-1287.
• 5 Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opinion on Investigational Drugs 2010; 19 (08) 995-1005.
• 6 Widler L. Calcilytics: antagonists of the calciumsensing receptor for the treatment of osteoporosis. Future Medicinal Chemistry 2011; 03 (05) 535-547.
• 7 Nemeth EF. The search for calcium receptor antagonists (calcilytics). Journal of Molecular Endocrinology 2002; 29 (01) 15-21.
• 8 Balan G, Bauman J, Bhattacharya S. et al. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorganic & Medicinal Chemistry Letters 2009; 19 (12) 3328-3332.
• 9 Fukumoto S, Namba N, Ozono K. et al. Causes and Differential Diagnosis of Hypocalcemia - Recommendation Proposed by Expert Panel Supported by Ministry of Health, Labour and Welfare, Japan. Endocrine Journal 2008; 55 (05) 787-794.
• 10 Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. American Journal of Physiology-Renal Physiology 2010; 298 (03) F485-F499.
• 11 Jung JS, Foroud TM, Eckert GJ. et al. Association of the Calcium-Sensing Receptor Gene with Blood Pressure and Urinary Calcium in African-Americans. Journal of Clinical Endocrinology & Metabolism 2009; 94 (03) 1042-1048.
• 12 Justinich CJ, Mak N, Pacheco I. et al. The extracellular calcium-sensing receptor (CaSR) on human esophagus and evidence of expression of the CaSR on the esophageal epithelial cell line (HET-1A). American Journal of Physiology-Gastrointestinal and Liver Physiology 2008; 294 (01) G120-G129.
• 13 Geibel JP, Hebert SC. The Functions and Roles of the Extracellular Ca(2+)-Sensing Receptor along the Gastrointestinal Tract. Annual Review of Physiology 2009; 71: 205-217.
• 14 Bandyopadhyay S, Tfelt-Hansen J, Chattopadhyay N. Diverse Roles of Extracellular Calcium-Sensing Receptor in the Central Nervous System. Journal of Neuroscience Research 2010; 88 (10) 2073-2082.
• 15 Marie PJ. The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis. Bone 2010; 46 (03) 571-576.
• 16 John MR, Widler L, Gamse R. et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 2011; 49 (02) 233-241.
• 17 Kiefer L, Leiris S, Dodd RH. Novel calcium sensing receptor ligands: a patent survey. Expert Opinion on Therapeutic Patents 2011; 21 (05) 681-698.
• 18 Shinagawa Y, Inoue T, Katsushima T. et al. Discovery of a Potent and Short-Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone. Acs Medicinal Chemistry Letters 2011; 02 (03) 238-242.
• 19 Kumar S, Matheny CJ, Hoffman SJ. et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010; 46 (02) 534-542.
• 20 Letz S, Rus R, Haag C. et al. Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. Journal of Clinical Endocrinology & Metabolism 2010; 95 (10) 229-233.
• 21 Rybczynska A, Jurska-Jasko A, Boblewski K. et al. Blockade of Calcium Channels and At1 Receptors Prevents the Hypertensive Effect of Calcilytic Nps 2143 in Rats. Journal of Physiology and Pharmacology 2010; 61 (02) 163-170.
• 22 Trivedi R, Mithal A, Chattopadhyay N. Pharmacological Manipulation of Calcium-Sensing Receptor: Prospect As Anabolic Therapy for Postmenopausal Osteoporosis. Drugs of the Future 2009; 34 (10) 803-809.